Critical Therapeutics Inc (fka CRTX)

[trendzone]

It's not if, just when the shorts get blown out again like yesterday over $3.00, perhaps after hours when the spread is larger and any big uptick in buy side volume can get ugly red for shorts pretty quickly.

[BooDog]

Simple gap and trap right before their offering looks like to me.

https://www.sec.gov/ix?doc=/Archives/edgar/data/1817944/000119312522101090/d248113ds1.htm

From the 11th.

[BooDog]

It's a gapper! Nice early volume. Who's going to win this round? Bulls or bears?

.99 to 1.20's.

[weedisgreen]

I'm in. Time to go up!

[da_stock_analyst]

4 Swing Trade Ideas #LGVN ?? #CRTX ?? #GRTX ?? #QLGN ?? Technical analysis with entry and exit!

[BeamMeUpScotty]

Question - is shorting allowed in out of hours trading?

[Motba]

Gapper and run tomorrow…. GL all!

[Motba]

Congrats!!! $$$ making next few weeks guaranteed!!!

[ok2buy]

This is trading like there is going to be news. Someone in the know loading up? Could shape up for an interesting tomorrow. Best of luck to the retailers and the longs./ok2

[Microlytics]

In for 1000 shares at $15.90 let's see

[Motba]

Looking good!!!! $$$

[ok2buy]

This one is set to run back up. How high, that's the question. If you bought on the drop, you should be happy. Hold and prosper./ok2

[georgie18]

CRTX...$13.20...Oversold Pincher Squeeze setting up here...Open Gap to fill in the $57 range...

Looks like a great entry set up here as CRTX finds a base following the News Dip...imo...we shall see...

Chart...https://schrts.co/HRmqFfSq ...

Shares of Cortexyme Inc. CRTX, -7.43% tumbled 72.7% in trading on Wednesday, the day after the company said a late-stage clinical trial evaluating its experimental Alzheimer's disease treatment failed to meet the study's endpoints. Cortexyme's stock is down 43.3% this year; the S&P 500 SPX, +0.19% is up 21.8%.

[McMagyar]

To make it even more complicated
Saw post where MMSE score were below 18 on half? Participants?

Is that correct?

So then to compare the data ..

Would only want to see results on
Targeted Gingivitis Positives Dosed( High dosage) that started trial above 20 MMSE..



That is the number you want to see..

What was this result after one year?

[McMagyar]

I didn’t really follow cassava until after
The longer review..think 88% response..
Some reversal..the numbers are impressive..Anavex is the alpha drug foe human health.. and annovis has an awesome multi pronged nervous system drug..

The next five years are going to be exciting

[TempePhil]

I see what you mean. I think biogens is aducanumab. I have a hard time remembering that too! It doesn't exactly roll off your tongue.

Yeah I don't know what to say about fda. They certainly screwed up with biogen. Now all the other plaque fighters, with poor data want to get their drug approved too...well you did it for biogen!!
I don't know how Cortexymes drug will end up. There are new drugs in the works, like anavex's too. I could see a cocktail of the effective drugs used...NOT biogens. Unfortunately the pharma industry moves at a snails pace.

I don't know where the sava drug stands. I am bothered by the apparently edited pictures.

[McMagyar]

Sorry about typos.. would normally go back and fix.. but can’t do it from cell..
Brain sweller drug by Biogen if that helps

[McMagyar]

Tempe
Here is the question I ask..

Slowing the decline by 50% would have been great 10 years ago..
Would have killed it..
destroyed Memantine and other fake AD
Drug ( which I can’t remember- guess why)

But here we are now..

So this drug fails because I’m this order
Other deugs will render it to the sideline..
Anavex, Cassava, Annovis..

All three will clinically kick it’s ass..

Hindsight 20/20.. here we are..

Strategically right now WE know this drug at high dose can help millions of people right now that signal high expression of target..( again can’t remember name of target.. dimentia sucks ass)
BUT since that was NOT goal of Trial or endpoint..
the FDA is Most likely going to continue feeding the memory care institution with human cattle.. right?

Can’t fight the FDA.. can you ???




None of these bastards are making this Human!!!

Where are the people that reduced less ??
Put them on camera.. let them beg for access to the country.. do something!!

Anavex (80% save) will be here in less than a year..maybe it will work even better with those expressing ……
Cassava (8x% success) will be here in 2 years..
Annnovis maybe three..

This drug could act as adjuvant for one or maybe all three.. reducing those who express that signal..


So the DRUG has value..

Is there a type of dementia wherein this over expression is more greatly exhibited?
The test for the expression is easy inexpensive?

I don’t know where the MC value shoul be ,, but we do have to quit throwing away drugs that show a targeted success because not everyone got better..

Wasn’t there a nicotine targeted drug that did well but screwed up their Endpoint so it failed?


Yes Biogen’s blain dweller rocks it out of FDA because the right advocates were on board.. $$$ talks .. even when it’s your parents.. we suck

[TempePhil]

Hello McMagyar. Unfortunately, they did not report MMSE data and it was a secondary endpoint test only. They will probably report that at the November meeting.

They did two other tests for primary endpoints. One was called ADAS-Cog, which had the cognition improvement of 57% better than placebo. The other test they did was ADCS-ADL, which clearly failed, apparently because of the pandemic related questions.

Please allow me to rephrase my summary. The company expected the best response to be from the patients that had the P. gingivalis bacteria. And indeed these patients when given the HIGH dose, did better than the other patients that did NOT have the bacteria and the ones that got the placebo. In fact, from the start (baseline) they declined only about 43% as much as the placeboed patients, at the end (11months). These were the 'super responders'. They declined, but less than half as much as not getting anything at all. (actually 43%)

Now the question I always ask, is "How many of all the people with AD will be helped?". The answer is 37.6%. Of all the AD patients, 37.6% had the bacteria present. So, if you took 1000 people with AD and gave them 80mg COR388, 376 would perform the best, only declining 43% as much as the other 624. The 624 might be helped a little, but we cannot tell from the data the company PRed.

From what I remember of the Biogen data, this COR388 is better. COR388 works better (43% decline) and works on more people 37.6%. I would much rather try COR388 than the Biogen drug!

As a point of reference to say A2-73. If you recall the A2-73 super-responders did not decline at all, but actually improved. I also believe the A2-73 super responders will be 57%. These are the people with the wild type genes.

Hope this is clearer. All is in my humble opinion of course!

[McMagyar]

Thx Tempe..
I still dont think these results are being framed in human terms..

IF someone who has mild ad: mmse 22. And displays the pre selected signal
takes the high dose of medicine ..
there MMsE In One year at high dose will be;

IMproved?
Stabilized?
Decline but less than placebo:

Normal ad patient declined by four points to 18 MMSE..

Where is the High Dose Expression patient average MMSE?

[TempePhil]

Analysis of the GAIN Trial PR data:

Regarding the cognitive tests: The subgroup with (P. gingivalis aka PG) constituted (242/643) 37.6% of all the subjects. The high dose group with PG, showed a 57% slowing of cognitive decline for ADAS-COG11. This is a significant improvement, but did not meet their predicted improvement of 2.5 points. I think they actually attained ~1.71 points of improvement ( approximately 57% of 2 to 4, being ~1.71 points). There was a dose improvement with the high dose over the 40mg dose, but the 40mg dose had a high p-value, emphasizing the need for the higher dose for better efficacy, but also indicating that the lower dose is near the bottom of the useable dose range.

In summary, if any group of people with AD, took COR388, 37.6% of them would see cognition decline of 43% (much better than 100%).
IIRC the high dose gives much better efficacy than the BIIB aducanumab!

There was also an endpoint test using Activities of Daily Living(ADL). This endpoint was also not met. Why? The company rightly raises the issue that many of these questions are affected by the pandemic lockdown. For example, there are questions about travel and shopping.
Surely, the company will raise this issue with the FDA. What will be the outcome?

I dont know if this board is active, but I thought I would pass this along.

[Motba]

Lotto $50 11/19 calls.. do or die…

[lvhd]

In some 15 calls

[Porteño]

Finally starting a recovery. Let's see if it has legs.

$CRTX

[bcapps66]

And the bleeding continues :(

[Porteño]

-75% vs -76%... meh

Can still recover significantly rest of this week.

Let's see...

[bcapps66]

Just when you think it wouldn't go lower....it does grrrrrr

[bcapps66]

No bounce at all today...it just fell and splat!

[Porteño]

Yes, extremely oversold.

Not for the faint of heart since this is catching a falling knife, but good odds down here IMO.

$CRTX

[bcapps66]

Wow...down from $100 a month ago

[Porteño]

I agree. I like the chart right now. Intraday showing some nice positive divergence. -75% seems a bit overdone.

JMHO

$CRTX

[McMagyar]

The drug appears to work for targeted group.. obvious disappointment
But what was market expecting? That drug would affect those not experiencing gingivit over expression?

Why would it?

Are shorts just taking advantage of
the timing or was the after market condense Xena cal terrible?

[Penny Double]

RUN!!!

[TheFinalCD]

OUCH~!

[TheFinalCD]

anyone holding through this? https://www.reuters.com/business/healthcare-pharmaceuticals/cortexymes-alzheimers-treatment-fails-meet-main-goals-study-2021-10-26/

CRTX

[whosleftholdindabag]

I'll be looking at $7-$9 range for a starter position of 100k shares. GLTA

[whosleftholdindabag]

Hello everybody, I'll be watching for the stock to bottom in the next couple days. I believe this is an over reaction. GLTA

[ranchhand71]

Merrill 6-25-21 report says:
Cortexyme, Inc
Updating our atuzaginstat pricing
assumptions following Aduhelm approval
Reiterate Rating: NEUTRAL | PO: 58.00 USD | Price: 51.66 USD
Aduhelm sets a pricing precedent in AD
Following the recent approval of BIIB’s (covered by Geoff Meacham) amyloid betadirected antibody, Aduhelm (aducanumab), in Alzheimer’s disease (AD), we are revisiting
our CRTX model to update pricing assumptions for atuzaginstat (COR388) in AD to
directionally reflect how BIIB priced Aduhelm (~$56K/year for maintenance dosing). We
increase our pricing assumption for atuza’ to $30K from $15K in the US ($15K from
$7.5K ROW), based on conversations with mgmt, and assume no annual price increases
(prev. 5%) as BIIB has pledged not to raise prices near term. We note our price
assumption is lower than Aduhelm, as we acknowledge there is public pushback on
Aduhelm price given the large addressable population and lack of supportive functional
data. We are not updating our likelihood of success (LoS) for atuza’ in AD as we don’t
know, based on the approval of Aduhelm, if the FDA has changed their perspective on
regulatory requirements for AD. Also, atuza’s MOA of targeting gingipain (bacterial toxin)
is different from Aduhelm’s mechanism, thus we think there is little read through to
CRTX’s program. Recall atuzaginstat is currently in the ongoing phase 2/3 GAIN trial in
mild-to-moderate AD with topline data expected in 4Q (more below), and the open label
extension portion of the trial was placed on partial clinical hold following a review of
hepatic adverse events. We continue to view AD as an indication in high need of
disease-modifying therapies, but we await further validation of the gingipain mechanism
and clarity on the long-term safety profile to better evaluate atuzaginstat’s role in
treating the disease. In our DCF-based model we also we roll the qtr. Atuzaginstat in AD
is currently the primary driver in our model contributing $52/sh to our PO with
estimated risk-adj. peak sales of $1.7bn by 2035 under our 10% LoS and 15% US/ 10%
ROW peak market share assumptions. Our model changes result in a new PO of $58
(previous $40) as we reiterate our Neutral rating.
GAIN readout by YE is next major catalyst
Recall GAIN passed its interim futility analysis in December with the Data Monitoring
Committee’s decision to continue as planned with 643 subjects. The co-primary
endpoints are changes from baseline in ADAS-Cog11 and CDR-SB at wk 48, and topline
is expected in 4Q. GAIN also has a dental substudy (n=233) on pocket depth and clinical
attachment level that will potentially provide proof of concept in periodontal disease.

[infitvest]

Here is some simple math for NEW INVESTORS!!!!

PFizer owns roughly 2 million shares out of the 29 outstanding right? That represents less then .03% of Pfizers net worth. SO, they (Pfizer) can afford the bad news in November (shall it happen ;)). Ask yourself as a new investor if you can take the same type a hit a 215BILLION dollar company can!?

A .03% (that's .0003) investment of your net worth is and should be considered a "safe" investment in #CRTX $CRTX


If you are millionaire, that would be 1Million X .0003 = $300 investment. Obviously needs to be dialed down if you are not worth that much.

Other recommendation to consider? IMO $AVXL #AVXL
. Pipeline for multiple indications with 3 years of proven safety. Not 1 shot on goal with their program. Patient production for multiple drugs till 2039!

****Do your own DD and you'll see everything I posted is true. Don't be a misinformed investor****

[infitvest]

Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold
Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold


QUESTIONS INVESTORS SHOULD BE ASKING THEMSELVES:
WHAT HAPPENS ON EITHER THE "EFFECTIVE" 40MG or 80MG DOSE per FDA?** Maybe someone will argue it doesn't happen with the 40mg dose? I argue that's not the most effective dose and also argue that its only a matter of time till the same issues with the liver happen**

*In February 2021 (Only 3 months ago), the FDA placed a partial clinical hold on GAIN because of liver abnormalities in some participants (press release). Dosing in the open-label extension was stopped. Cortex characterized the liver effects as reversible and showing no risk of long-term effects. (How were they reversible? by discontinuing the medicine? How does that help LONG TERM TREATMENT?*

****If I was a new CRTX investor****, the 15 minutes of researching would pull up a bunch of older articles making claims (like those have NEVER been done before). Followed by articles highlighting the CEO selling massive amounts of shares, Followed my investigational lawsuits, Followed by the FDA HAULTING their extension due safety, Followed by a really bad performance by the CEO in April (pipeline question = bad, fda explanation = bad, looking visibly upset cause you have to answer why your drug isn't safe long term = bad.... )The individual questioning her was incredibly smart to pretty much let investors know that CRTX has a extremely limited chance at AD approval.

From Yahoo Finance:
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [e-mail] or 888-476-6529, ext. 7980.

The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.


On February 15, 2021, Cortexyme announced receipt of "a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension (OLE) phase of the company's ongoing Phase 2/3 study, the GAIN Trial." Cortexyme advised that, as a result of the partial clinical hold, "no new participants will be enrolled in the OLE and currently enrolled OLE participants will be discontinued." According to the Company, "the partial clinical hold was initiated following the review of hepatic adverse events in the atuzaginstat trial by the FDA."

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[e-mail]
888-476-6529 ext. 7980

[infitvest]

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX

Yahoo Finance

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Cortexyme, Inc. ("Cortexyme" or the "Company") (NASDAQ: CRTX). Such investors are advised to contact Robert S. Willoughby at [e-mail] or 888-476-6529, ext. 7980.

The investigation concerns whether Cortexyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.


On February 15, 2021, Cortexyme announced receipt of "a letter from the U.S. Food and Drug Administration (FDA) stating that a partial clinical hold has been placed on atuzaginstat (COR388) impacting the open-label extension (OLE) phase of the company's ongoing Phase 2/3 study, the GAIN Trial." Cortexyme advised that, as a result of the partial clinical hold, "no new participants will be enrolled in the OLE and currently enrolled OLE participants will be discontinued." According to the Company, "the partial clinical hold was initiated following the review of hepatic adverse events in the atuzaginstat trial by the FDA."

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[e-mail]
888-476-6529 ext. 7980

[infitvest]

Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold

Up­dat­ed: Cor­texyme's un­ortho­dox Alzheimer's ap­proach tripped up by FDA hold

[infitvest]

Alzheimer's drug developer sheds third of value after part of trial halted

[infitvest]

why is this board so dead??? everyone sell like the insiders?

[infitvest]

Is safety long term an issue?

[dealerschool2006]

CRTX seems to have bounced back from EOY sell-off...

[dealerschool2006]

goodnews for CRTX and it falls with high volume yet options are strong...why???

https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-uthr-crtx-tol-2020-12-04

[TFMG]

$CRTX | #Cortexyme Inside Buying Continues




Insider buys Continue in the stock
EPIQ Capital Group, LLC IA/Managing Member of 10% Owne Jun 12 Buy 44.06 2,440 $107,506
EPIQ Capital Group, LLC IA/Managing Member of 10% Owne Jun 11 Buy 44.32 6,600 $292,512

PLEASE GIVE US A LIKE IF YOU FIND OUT CONTENT HELPFUL, THANK YOU.

[dinogreeves]

The next one that is going to run like CRTX is NR*BO. 280,000 float.

[crudeoil24]

Cortexyme Announces $125M Private Placement; 2.5M Shares @$50/Share
9:03 pm ET February 5, 2020 (Benzinga) Print
Cortexyme, Inc. (Nasdaq: CRTX) today announced that it has entered into stock purchase agreements with a group of institutional investors and an entity affiliated with a member of the Company's Board of Directors in connection with a private placement of its common stock. The transaction is expected to result in gross proceeds to the Company of $125 million, before deducting placement agent fees and other offering expenses. The Company plans to use the net proceeds from the private placement primarily to advance clinical development, as well as for general corporate purposes.

The Company will issue 2,500,000 shares of common stock for a purchase price of $50.00 per share, which was based upon the volume weighted average price of the Company's common stock since January 1, 2020, and represents a 9.6% premium to the closing price of the Company's common stock on February 5, 2020.

The closing of the private placement is subject to certain conditions and is expected to occur on Monday, February 10, 2020.

BofA Securities and Jefferies served as placement agents for the private placement.

0
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.